ISU ABXIS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,710 KRW | +3.71% |
|
-9.45% | +10.91% |
| Sales 2024 * | 71.3B 51.76M | Sales 2025 * | 85B 61.71M | Capitalization | 233B 169M |
|---|---|---|---|---|---|
| Net income 2024 * | 6B 4.36M | Net income 2025 * | 9B 6.53M | EV / Sales 2024 * | 2.48 x |
| Net cash position 2024 * | 56.8B 41.24M | Net cash position 2025 * | 61.6B 44.72M | EV / Sales 2025 * | 2.02 x |
| P/E ratio 2024 * |
36.9
x | P/E ratio 2025 * |
23.7
x | Employees | 95 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 63.46% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.71% | ||
| 1 week | -9.45% | ||
| Current month | +1.05% | ||
| 1 month | +3.71% | ||
| 3 months | +17.93% | ||
| 6 months | +9.64% | ||
| Current year | +10.91% |
1 week
6 370.00
7 090.00
1 month
6 140.007 980.00
Current year
5 250.007 980.00
1 year
5 250.008 410.00
3 years
4 950.0025 000.00
5 years
3 500.0025 000.00
10 years
3 500.0025 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yup Hwang
CEO | Chief Executive Officer | 59 | - |
Soo-Hyeon Jung
PRN | Corporate Officer/Principal | 50 | - |
Chang-Bok Choi
AUD | Comptroller/Controller/Auditor | 53 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yup Hwang
CEO | Chief Executive Officer | 59 | - |
Sang-Ho Park
BRD | Director/Board Member | 62 | - |
Hyeong-Rae Kim
BRD | Director/Board Member | 68 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 6,710 | +3.71% | 174,238 |
| 24-04-17 | 6,470 | -2.12% | 99,018 |
| 24-04-16 | 6,610 | -5.03% | 179,177 |
| 24-04-15 | 6,960 | -5.95% | 369,003 |
| 24-04-12 | 7,400 | -0.13% | 203,159 |
End-of-day quote Korea S.E., April 17, 2024
More quotes
ISU Abxis Co., Ltd. is a Korea-based company mainly engaged in the biopharmaceutical business. The Company operates its business under two divisions: antibody therapeutics business division and diagnostic business division. Its antibody therapeutics business division engages in the development of Cloticab, which is a monoclonal therapeutic antibody for thrombus. Its diagnostic business division engages in the provision of genetic testing services and chemotherapy response assay services for cancer examination.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +10.91% | 163M | |
| -5.65% | 84.57B | |
| +3.95% | 39.93B | |
| -26.37% | 27.93B | |
| +52.09% | 24.21B | |
| -6.59% | 17.17B | |
| -32.37% | 13.93B | |
| -10.45% | 12.3B | |
| -15.88% | 11.84B | |
| -2.85% | 7.91B |
- Stock Market
- Equities
- A086890 Stock
